Viral spike protein epitope

A viral spike protein epitope is a specific region or peptide sequence on the surface glycoprotein ("spike") of an enveloped virus—most notably the spike glycoprotein of coronaviruses such as SARS-CoV-2—that is recognized by components of the immune system, particularly B cell receptors/antibodies and T cell receptors[1][3][5]. Such epitopes can be linear or conformational and may be located in functionally critical domains such as the receptor-binding domain (RBD), the N-terminal domain (NTD), or conserved regions of the fusion peptide and heptad repeat regions of the spike S2 subunit[2][5][6]. Recognition of spike protein epitopes underpins the efficacy of neutralizing antibody therapies and vaccines, but certain epitopes can also facilitate viral immune evasion or, in rare instances, enhance viral entry (by modulating spike conformation or through ADE)[1]. Spike protein epitopes are primary targets for both therapeutic antibodies and vaccine design due to their role in mediating viral attachment and membrane fusion, and their accessibility on the viral surface[3][4][7]. Mutations, deletions, or glycosylation at these epitope sites can significantly influence antigenicity, vaccine efficacy, and the therapeutic potential of monoclonal antibodies[3][4].

Other names

Spike glycoprotein epitopeS protein epitopeSpike protein B cell epitopeCoronavirus spike epitopeSARS-CoV-2 spike epitope

Neutralization: Antibodies bind to spike protein epitopes and block viral attachment or fusion; Enhancement: In rare cases, antibodies can enhance infection via specific epitope interactions (antibody-dependent enhancement, ADE); Blocking receptor interaction: Preventing spike protein from binding its host receptor (for example, ACE2 in SARS-CoV-2)